{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T20:48:15Z","timestamp":1790887695792,"version":"4.1.0"},"reference-count":25,"publisher":"American Society of Hematology","issue":"13","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/legalcode"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,9,29]]},"DOI":"10.1182\/blood.2022016211","type":"journal-article","created":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T20:06:26Z","timestamp":1659384386000},"page":"1565-1569","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":13,"title":["Anti-CD37 \u03b1-amanitin\u2013conjugated antibodies as potential therapeutic weapons for Richter syndrome"],"prefix":"10.1182","volume":"140","author":[{"given":"Tiziana","family":"Vaisitti","sequence":"first","affiliation":[{"name":"1Department of Medical Sciences,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Vitale","sequence":"additional","affiliation":[{"name":"2Department of Molecular Biotechnologies and Health Science, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matilde","family":"Micillo","sequence":"additional","affiliation":[{"name":"1Department of Medical Sciences,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9015-8407","authenticated-orcid":false,"given":"Lorenzo","family":"Brandimarte","sequence":"additional","affiliation":[{"name":"1Department of Medical Sciences,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8940-1406","authenticated-orcid":false,"given":"Andrea","family":"Iannello","sequence":"additional","affiliation":[{"name":"1Department of Medical Sciences,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro Giulio","family":"Papotti","sequence":"additional","affiliation":[{"name":"3Department of Oncology, University of Turin, Turin, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozren","family":"Jaksic","sequence":"additional","affiliation":[{"name":"4Department of Hematology, University Hospital Dubrava, Zagreb, Croatia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0188-0885","authenticated-orcid":false,"given":"Gianluca","family":"Lopez","sequence":"additional","affiliation":[{"name":"5Department of Clinical and Molecular Medicine, Sapienza University and Sant'Andrea Hospital, Rome, Italy; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3159-5380","authenticated-orcid":false,"given":"Arianna","family":"Di Napoli","sequence":"additional","affiliation":[{"name":"5Department of Clinical and Molecular Medicine, Sapienza University and Sant'Andrea Hospital, Rome, Italy; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Carlos","family":"Cutrin","sequence":"additional","affiliation":[{"name":"2Department of Molecular Biotechnologies and Health Science, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Orlik","sequence":"additional","affiliation":[{"name":"6Heidelberg Pharma Research GmbH, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4634-1180","authenticated-orcid":false,"given":"Michael","family":"Kulke","sequence":"additional","affiliation":[{"name":"6Heidelberg Pharma Research GmbH, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Pahl","sequence":"additional","affiliation":[{"name":"6Heidelberg Pharma Research GmbH, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0632-5036","authenticated-orcid":false,"given":"Silvia","family":"Deaglio","sequence":"additional","affiliation":[{"name":"1Department of Medical Sciences,"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"15","key":"2022092915292157200_B1","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1182\/blood-2013-03-489518","article-title":"Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome","volume":"122","author":"Chigrinova","year":"2013","journal-title":"Blood."},{"issue":"2","key":"2022092915292157200_B2","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1053\/j.seminoncol.2016.02.012","article-title":"Richter syndrome: pathogenesis and management","volume":"43","author":"Rossi","year":"2016","journal-title":"Semin Oncol."},{"issue":"12","key":"2022092915292157200_B3","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1182\/blood-2010-09-302174","article-title":"The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation","volume":"117","author":"Rossi","year":"2011","journal-title":"Blood."},{"key":"2022092915292157200_B4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/asheducation-2018.1.1","article-title":"On the architecture of translational research designed to control chronic lymphocytic leukemia","volume":"2018","author":"Hallek","year":"2018","journal-title":"Hematology Am Soc Hematol Educ Program."},{"issue":"4","key":"2022092915292157200_B5","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1007\/s11864-022-00973-1","article-title":"Novel approaches for the treatment of patients with Richter\u2019s syndrome","volume":"23","author":"Iannello","year":"2022","journal-title":"Curr Treat Options Oncol."},{"issue":"26","key":"2022092915292157200_B6","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1182\/blood-2017-02-765685","article-title":"Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL","volume":"129","author":"Ding","year":"2017","journal-title":"Blood."},{"issue":"2","key":"2022092915292157200_B7","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/bjh.15508","article-title":"Use of PD-1 (PDCD1) inhibitors for the treatment of Richter syndrome: experience at a single academic centre","volume":"185","author":"Rogers","year":"2019","journal-title":"Br J Haematol."},{"issue":"24","key":"2022092915292157200_B8","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1182\/blood.2020008404","article-title":"ROR1 targeting with the antibody-drug conjugate VLS-101 is effective in Richter syndrome patient-derived xenograft mouse models","volume":"137","author":"Vaisitti","year":"2021","journal-title":"Blood."},{"issue":"8","key":"2022092915292157200_B9","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1038\/sj.leu.2403822","article-title":"Aberrant expression of tetraspanin molecules in B-cell chronic lymphoproliferative disorders and its correlation with normal B-cell maturation","volume":"19","author":"Barrena","year":"2005","journal-title":"Leukemia."},{"key":"2022092915292157200_B10","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3389\/fphys.2015.00091","article-title":"Tetraspanins as therapeutic targets in hematological malignancy: a concise review","volume":"6","author":"Beckwith","year":"2015","journal-title":"Front Physiol."},{"issue":"26","key":"2022092915292157200_B11","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1182\/blood-2016-05-715094","article-title":"Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma","volume":"128","author":"Xu-Monette","year":"2016","journal-title":"Blood."},{"issue":"20","key":"2022092915292157200_B12","doi-asserted-by":"crossref","first-page":"3500","DOI":"10.1182\/blood-2013-05-505685","article-title":"A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies","volume":"122","author":"Deckert","year":"2013","journal-title":"Blood."},{"issue":"1","key":"2022092915292157200_B13","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/bjh.13099","article-title":"Otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR(\u2122) therapeutic protein, for relapsed or refractory NHL patients","volume":"168","author":"Pagel","year":"2015","journal-title":"Br J Haematol."},{"issue":"7","key":"2022092915292157200_B14","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1158\/1535-7163.MCT-15-0067","article-title":"AGS67E, an anti-CD37 monomethyl auristatin E antibody-drug conjugate as a potential therapeutic for B\/T-cell malignancies and AML: a new role for CD37 in AML","volume":"14","author":"Pereira","year":"2015","journal-title":"Mol Cancer Ther."},{"issue":"6","key":"2022092915292157200_B15","doi-asserted-by":"crossref","first-page":"e0128816","DOI":"10.1371\/journal.pone.0128816","article-title":"Targeted cancer therapy with a novel anti-CD37 beta-particle emitting radioimmunoconjugate for treatment of non-Hodgkin lymphoma","volume":"10","author":"Repetto-Llamazares","year":"2015","journal-title":"PLoS One."},{"issue":"11","key":"2022092915292157200_B16","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1007\/s00259-019-04417-1","article-title":"Targeting B-cell malignancies with the beta-emitting anti-CD37 radioimmunoconjugate 177Lu-NNV003","volume":"46","author":"Maaland","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"4","key":"2022092915292157200_B17","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1007\/s10637-020-01054-6","article-title":"A phase Ib, open-label, dose-escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with gemcitabine and oxaliplatin in patients with relapsed\/refractory diffuse large B-cell lymphoma","volume":"39","author":"Balzarotti","year":"2021","journal-title":"Invest New Drugs."},{"issue":"4","key":"2022092915292157200_B18","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1007\/s10637-020-01056-4","article-title":"A phase Ib, open label, dose escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with ibrutinib in patients with relapsed\/refractory chronic lymphocytic leukemia","volume":"39","author":"Danilov","year":"2021","journal-title":"Invest New Drugs."},{"issue":"17","key":"2022092915292157200_B19","doi-asserted-by":"crossref","first-page":"4091","DOI":"10.1182\/bloodadvances.2020002583","article-title":"Phase 1\/2a study of 177Lu-lilotomab satetraxetan in relapsed\/refractory indolent non-Hodgkin lymphoma","volume":"4","author":"Kolstad","year":"2020","journal-title":"Blood Adv."},{"issue":"4","key":"2022092915292157200_B20","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1111\/bjh.14464","article-title":"Randomized phase 2 study of otlertuzumab and bendamustine versus bendamustine in patients with relapsed chronic lymphocytic leukaemia","volume":"176","author":"Robak","year":"2017","journal-title":"Br J Haematol."},{"issue":"10","key":"2022092915292157200_B21","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1038\/s41375-019-0475-z","article-title":"Phase 1 first-in-human trial of the anti-CD37 antibody BI 836826 in relapsed\/refractory chronic lymphocytic leukemia","volume":"33","author":"Stilgenbauer","year":"2019","journal-title":"Leukemia."},{"issue":"5","key":"2022092915292157200_B22","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.molcel.2008.04.023","article-title":"The RNA polymerase II trigger loop functions in substrate selection and is directly targeted by alpha-amanitin","volume":"30","author":"Kaplan","year":"2008","journal-title":"Mol Cell."},{"issue":"11","key":"2022092915292157200_B23","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.3324\/haematol.2017.173419","article-title":"Targeting metabolism and survival in chronic lymphocytic leukemia and Richter syndrome cells by a novel NF-\u03baB inhibitor","volume":"102","author":"Vaisitti","year":"2017","journal-title":"Haematologica."},{"issue":"24","key":"2022092915292157200_B24","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1182\/blood.2020010187","article-title":"Synergistic efficacy of the dual PI3K-\u03b4\/\u03b3 inhibitor duvelisib with the Bcl-2 inhibitor venetoclax in Richter syndrome PDX models","volume":"137","author":"Iannello","year":"2021","journal-title":"Blood."},{"issue":"13","key":"2022092915292157200_B25","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1158\/0008-5472.CAN-17-4004","article-title":"Novel Richter syndrome xenograft models to study genetic architecture, biology, and therapy responses","volume":"78","author":"Vaisitti","year":"2018","journal-title":"Cancer Res."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/140\/13\/1565\/1922838\/bloodbld2022016211.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/140\/13\/1565\/1922838\/bloodbld2022016211.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T15:29:54Z","timestamp":1664465394000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/140\/13\/1565\/486081\/Anti-CD37-amanitin-conjugated-antibodies-as"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,29]]},"references-count":25,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2022,9,29]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2022016211","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,29]]}}}